Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen with or without Visudyne PDT in neovascular age-related macular degeneration
2004-004867-31Phase 3Completed
- Sponsor
- (OSI) Eyetech Pharmaceuticals, Inc
- Start
- Feb 2005
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration and Subretinal neovascularization comparing Macugen + sham PDT with Macugen + Visudyne PDT (2 arms). Started Feb 2005; status: completed.
02
Drugs
pegaptanib sodiumverteporfin
03
Conditions
exudative macular degenerationSubretinal neovascularization
Beyond the preview
Go deeper on 2004-004867-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004867-31.